V. Gorbounova

发表

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

M. Casey, S. Stein, C. Geyer, 2008, Breast Cancer Research and Treatment.

Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.

B. Erikstein, S. Verma, D. Miles, 2001 .

RAMUCIRUMAB THERAPY IN PATIENTS WITH ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: A SYSTEMATIC REVIEW

R. Cheng, M. Orlando, V. Gorbounova, 2017 .

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

R. Kimmig, H. Sommer, V. Gorbounova, 2007, Clinical Cancer Research.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification

R. Jensen, H. Sorbye, J. Scoazec, 2017, Neuroendocrinology.

O 6 -METHYLGUANINE-DNA-METHYLTRANSFERASE EXPRESSION IN PATIENTS WITH NEUROENDOCRINE TUMORS TREATED WITH АRANOZA-BASED REGIMENS

V. Gorbounova, A. Markovich, N. Orel, 2013 .

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

F. Fossella, M. Millward, J. Bérille, 2000 .

DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.

J. von Pawel, M. Reck, V. Gorbounova, 2014, Lung cancer.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

H. Sorbye, N. Fazio, C. Lombard-Bohas, 2017, Neuroendocrinology.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

H. Sorbye, N. Fazio, C. Lombard-Bohas, 2017, Neuroendocrinology.

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

J. O’Shaughnessy, C. Twelves, A. Bexon, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma

V. Gorbounova, A. Rasulov, M. Fedyanin, 2017, Cancer Chemotherapy and Pharmacology.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

A. Markoe, R. Tishler, D. Shin, 2007, The New England journal of medicine.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

R. Ramlau, J. von Pawel, J. R. Pereira, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

B. Monk, I. Vergote, A. Makhson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

R. Ramlau, J. von Pawel, P. Zatloukal, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

R. Ramlau, J. von Pawel, P. Zatloukal, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.

P. Fidias, R. Ramlau, J. von Pawel, 2006, Lung cancer.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

J. Lacy, M. Shah, C. Fuchs, 2019, The Lancet. Oncology.

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

Petr Zatloukal, R. Ramlau, P. Zatloukal, 2007 .

6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

R. Ramlau, P. Zatloukal, N. Leighl, 2007 .

P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

R. Ramlau, F. Fossella, M. Millward, 2005 .

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

D. Goldstein, C. Kaiser, V. Gorbounova, 2008, Oncology.

DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

M. Reck, V. Gorbounova, F. Grossi, 2012 .

Capecitabine monotherapy for patients with brain metastases from advanced breast cancer.

V. Gorbounova, M. Bychkov, D. Naskhletashvili, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

R. Jensen, G. Krejs, E. Krenning, 2018, Neuroendocrinology.

6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704

R. Ramlau, P. Zatloukal, N. Leighl, 2007 .

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

R. Ramlau, J. von Pawel, P. Zatloukal, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Goldstein, C. Kaiser, V. Gorbounova, 2008, Oncology.